[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626483":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":11,"studyPopulation":11,"armGroups":34,"interventions":50,"overallOfficials":11,"centralContacts":65,"locations":71,"responsibleParty":91,"collaborators":11,"id":93,"slug":11,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":11,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":11,"overallStatus":111,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Akeso","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Absolute change from baseline in pre-bronchodilator FEV1",null,"Up to week 12",{"measure":14,"description":11,"timeFrame":12},"Absolute change and percent change from baseline in FENO",[16,19,22],{"measure":17,"description":11,"timeFrame":18},"Adverse events (AEs), serious adverse events(SAEs)","Up to week 4",{"measure":20,"description":11,"timeFrame":21},"Serum AK139 concentration","Up to week 20",{"measure":23,"description":24,"timeFrame":21},"Immunogenicity characteristics of AK139","Number of participants with detectable anti-drug antibodies (ADA) and neutralizing antibodies (Nab) after treatment.",{"allocation":26,"interventionModel":27,"interventionModelDescription":11,"primaryPurpose":28,"observationalModel":11,"timePerspective":11,"maskingInfo":29},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":30,"maskingDescription":11,"whoMasked":31},"DOUBLE",[32,33],"PARTICIPANT","INVESTIGATOR",[35,40,43,46],{"label":36,"type":37,"description":11,"interventionNames":38},"AK139 regimen 1","EXPERIMENTAL",[39],"Drug: AK139",{"label":41,"type":37,"description":11,"interventionNames":42},"AK139 regimen 2",[39],{"label":44,"type":37,"description":11,"interventionNames":45},"AK139 regimen 3",[39],{"label":47,"type":37,"description":11,"interventionNames":48},"Placebo",[49],"Drug: Placebo",[51,56,59,62],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":11},"DRUG","AK139","AK139 regimen 1- subcutaneous injection.",[36],{"type":52,"name":53,"description":57,"armGroupLabels":58,"otherNames":11},"AK139 regimen 2- subcutaneous injection.",[41],{"type":52,"name":53,"description":60,"armGroupLabels":61,"otherNames":11},"AK139 regimen 3- subcutaneous injection.",[44],{"type":52,"name":47,"description":63,"armGroupLabels":64,"otherNames":11},"subcutaneous injection.",[47],[66],{"name":67,"role":68,"phone":69,"phoneExt":11,"email":70},"Guoqin Wang","CONTACT","+86 (0760) 8987 399","global.trials@akesobio.com",[72,83],{"facility":73,"status":11,"city":74,"state":11,"zip":11,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":11},"The First Affiliated Hospital of Guangzhou Medical University","Guangzhou","China","CN",{"type":78,"coordinates":79},"Point",[80,81],113.25,23.11667,{"lat":81,"lon":80},{"facility":84,"status":11,"city":85,"state":11,"zip":11,"country":75,"countryCode":76,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"Shanghai General Hospital","Shanghai",{"type":78,"coordinates":87},[88,89],121.45806,31.22222,{"lat":89,"lon":88},{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626483",false,"NCT07436221","A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma","A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK139 in the Treatment of Participants With Moderate to Severe Asthma","Inclusion Criteria:\n\n1. Diagnosed with asthma at least one year;\n2. Evidence of the reversibility of airflow limitation meets the requirements of the protocol;\n3. Pre-bronchodilator forced expiratory volume (FEV1) meets the requirements of the protocol at screening and baseline;\n4. Asthma Control Questionnaire 5-question version (ACQ-5) score≥1.5 at screening and baseline;\n5. The participants agree to use highly effective contraception methods from the moment of signing of the ICF to 3 months after the last dose of the investigational product.\n\nExclusion Criteria:\n\n1. Concomitant respiratory diseases that, as determined by investigators, may affect the evaluation of therapeutic effects or safety of the investigational product;\n2. A participant who experiences a severe asthma exacerbation at any time from 4 weeks prior to the screening up to and including the baseline;\n3. Allergic to any component of the investigational product or intolerant to basis treatment;\n4. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to;\n5. Other reasons the investigators believe that the participants are not suitable to enrolled in this study.","ALL","18 Years","65 Years",{"count":103,"type":104},160,"ESTIMATED","INTERVENTIONAL",[107],"PHASE2","This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.",[110],"Asthma","NOT_YET_RECRUITING","2026-02-25",{"date":114,"type":115},"2026-02-27","ACTUAL",{"date":117,"type":104},"2026-02-28",{"date":119,"type":104},"2027-02-26",{"name":5,"class":6},2]